Article Submission Process Streamlined for Clinica Chimica Acta and Related Journals
|
By LabMedica International staff writers Posted on 26 Sep 2022 |

Submitting an article for a scientific publication is an essential step in the research process, but finding the right journal can be challenging. Often authors' first choice of journal turns out not to be the right one, requiring them to resubmit their article elsewhere, which can be a complex and time-consuming process.
Now, an initiative by Elsevier BV (Amsterdam, Netherlands), one of the world's largest scientific publishers with around 300 journals including Clinica Chimica Acta, recognizes this process isn’t always smooth, and aims to help authors find the best journal match for their article, quickly and easily.
To achieve this, a dedicated team of scientific editors use their subject-matter knowledge to analyze manuscripts, provide guidance and tailored recommendations for transfers to another Elsevier journal, working closely with editors from both originating and destination journals.
Authors who have received rejections, either before or after peer review, will be able to accept a transfer offer to a more suitable journal.
The program is designed to make the editorial process smoother and more efficient, so that transferred articles will flow through the Elsevier editorial submission system. This comes with the advantage that in many instances, authors won’t need to reformat the article but still have the option to make revisions if they want. Additionally, previous comments from editors and referees can be transmitted with the manuscript, ensuring all parties benefit from previous insights.
The most common types of transmissions are pre-review and post-review, where editors of the destination journal will make their own assessment based on the materials they receive. When the editor of the originating journal considers that an article is acceptable for publication in another journal, Elsevier's scientific managing editor can offer an enhanced offer to authors such as Recommended Acceptance, Guaranteed Peer-Review or Fast-Track Processing by the suggested journal.
For Recommended Acceptance, provided that authors address comments from the original editors/referees, and follow the instructions given in the transfer offer, publication in the alternative journal is expected without further peer review. Laura Guilherme Luzia, a scientific managing editor at Clinica Chimica Acta, added, "Elsevier's Article Transfer Service team understands that authors are unique, and that each article deserves to find its most suitable journal."
Related Links:
Elsevier BV
Clinica Chimica Acta
Elsevier Article Transfer Service
Latest Clinical Chem. News
- Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke
- Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
- Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
- Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
- First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
- Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options
- Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
- Blood Test Patterns Improve Cancer Risk Assessment in Primary Care
- Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
- Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
- Blood Antibody Linked to Lower Depression and PTSD Symptoms After Brain Injury
- Blood Biomarker May Help Monitor Early Response to Lecanemab in Alzheimer’s Disease
- New Reference Material Aims to Improve Comparability of Angiotensin II Testing
- Childhood Blood Biomarkers May Reveal Early Heart, Kidney, and Metabolic Risks
- Blood Biomarker Study Reveals Early Signals of Future Cognitive Difficulties
- International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes
Channels
Molecular Diagnostics
view channel
Rapid Genetic Test Aims to Shorten Brain Tumor Diagnosis Time
Brain tumors can be highly aggressive and difficult to treat, and The Brain Tumour Charity describes them as the biggest cancer killer of children and adults under 40. With more than 100 recognized tumor... Read more
New Oncology Assays Deliver Precise Molecular Counts with MRD-Grade Sensitivity
Precise molecular monitoring is central to managing hematologic malignancies, but traditional PCR workflows can limit sensitivity, multiplexing, and result clarity. Limited sample volumes and fragmented... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read moreMicrobiology
view channel
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more
Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform is being featured in five abstracts at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.... Read moreTechnology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more





.jpg)

